Companies: 10,795·Total market cap: $144.5T
Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc.

BOLTNASDAQHealthcare● Active
$4.72
+$0.16(+3.51%)
Market Cap$9069796
P/E Ratio
52W High$7.35
52W Low$3.91
SEC Filings

Bolt Biotherapeutics, Inc. (BOLT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001641281 · BOLT · NASDAQ · as of Jun 8, 2026

Filing snapshot

278
Total Filings
10-Q
Latest Form
2026-05-12
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001641281 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001193125-26-104121
Primary Document
bolt-20251231.htm
Source: data.sec.gov · CIK 0001641281 · Accession 0001193125-26-104121

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
8-KCurrent Report
8-K
2026-05-12Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-12
View
ARSARS
ARS
2026-04-28
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
S-8Employee Stock Plan Registration
S-8
2026-03-12
View
10-KAnnual Report
10-K
2026-03-12
View
8-KCurrent Report
8-K
2026-03-12
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-02-26
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
10-QQuarterly Report
10-Q
2025-11-12
View
8-KCurrent Report
8-K
2025-11-12
View
Showing 1–15 of 176 filingsForm 4 / 144 hidden· 278 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001641281  |  Exchange: NASDAQ · Healthcare

Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) has submitted 278 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001641281, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Bolt Biotherapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Bolt Biotherapeutics, Inc. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical BOLT 10-K annual reports are available from 2015 through 2026.

Investors researching Bolt Biotherapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

BOLT SEC Filings · 8 questions

Bolt Biotherapeutics, Inc. (BOLT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 278 filings and access original documents at no cost. Bolt Biotherapeutics, Inc.'s CIK is 0001641281.

BOLT SEC filingsBolt Biotherapeutics, Inc. SEC documentsfind BOLT 10-K